[Paroxysmal kinesigenic dyskinesia: a channelopathy? Study of 19 cases]

Rev Neurol (Paris). 2009 Feb;165(2):164-9. doi: 10.1016/j.neurol.2008.08.009. Epub 2008 Oct 14.
[Article in French]

Abstract

Introduction: Paroxysmal kinesigenic dyskinesia (PKD) is characterized by brief episodes of dystonia and choreoathetosis triggered by sudden voluntary movements. Disease onset is seen in the first or second decade. The attacks typically last less than one minute. Three autosomal dominant PKD loci are identified: EKD1, EKD2 and EKD3. EKD1 has an overlap with the locus of the "Infantile Convulsion and Choreoathetosis (ICCA) syndrome". The favorable natural history, the episodic nature of the symptoms and their sensitivity to anticonvulsant therapy suggest channelopathy as a mechanism of PKD.

Patients and methods: We reviewed the clinical features, the family history, the treatment response, the evolution and the technical investigations in 19 affected individuals.

Results: All cases were idiopathic. Ten patients had a positive familial history. Three patients suffered from ICCA syndrome. Some atypical features were seen, such as the association of kinesigenic and nonkinesigenic attacks and the presence of migraine, ataxia, seizures and myoclonus. Acetazolamide responsiveness was seen in two patients.

Conclusion: The coexistence of PKD and nonkinesigenic dyskinesia in several patients confirms the earlier described presence of intermediary forms, nonrepresented in the current classification of paroxysmal dyskinesias. Our study results suggest channel dysfunction and basal ganglia involvement in the pathophysiology of PKD.

MeSH terms

  • Adolescent
  • Adult
  • Age of Onset
  • Amines / therapeutic use
  • Anticonvulsants / therapeutic use
  • Channelopathies / drug therapy
  • Channelopathies / genetics
  • Channelopathies / physiopathology*
  • Child
  • Child, Preschool
  • Chorea / drug therapy
  • Chorea / genetics
  • Chorea / physiopathology*
  • Chromosome Mapping
  • Cyclohexanecarboxylic Acids / therapeutic use
  • Female
  • Gabapentin
  • Humans
  • Infant
  • Male
  • Movement Disorders / drug therapy
  • Movement Disorders / genetics
  • Movement Disorders / physiopathology
  • Seizures / genetics
  • Seizures / psychology
  • Sex Ratio
  • Young Adult
  • gamma-Aminobutyric Acid / therapeutic use

Substances

  • Amines
  • Anticonvulsants
  • Cyclohexanecarboxylic Acids
  • gamma-Aminobutyric Acid
  • Gabapentin